This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Integer Holdings (ITGR) Q2 Earnings Miss Estimates, Down Y/Y
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect from weak segmental performance and margin contraction.
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect weak segmental performance.
OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from increase in RAYALDEE prescriptions.
Chemed (CHE) Q2 Earnings Beat Estimates, Margins Decline
by Zacks Equity Research
Chemed (CHE) witnesses solid revenue growth across key subsidiaries in Q2 earnings.
CONMED (CNMD) Q2 Loss Narrower Than Expected, Revenues Top
by Zacks Equity Research
CONMED's (CNMD) core units - General Surgery and Orthopedic Surgery - witnessed revenue decline in Q2.
Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) reported a drop in revenues at every key operating segment in Q2.
Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in third-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Baxter (BAX) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
Baxter's (BAX) second-quarter earnings reflect weak performance across Medication Delivery, Pharmaceutical and Advanced Surgery business units and contraction in margins.
Cerner (CERN) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) second-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in margins.
The Zacks Analyst Blog Highlights: Turning Point Brands, Medifast, Emergent BioSolutions, Thermo Fisher Scientific and Sempra Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Turning Point Brands, Medifast, Emergent BioSolutions, Thermo Fisher Scientific and Sempra Energy
The Zacks Analyst Blog Highlights: Microsoft, Tesla, Thermo Fisher Scientific, ABB and Suncor Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Tesla, Thermo Fisher Scientific, ABB and Suncor Energy
Jobless Claims Rise First Time Since March: 5 Defensive Picks
by Sreoshi Bera
The spike in unemployment claims and looming coronavirus fears have made markets volatile, making defensive picks lucrative investment options.
Top Stock Reports for Microsoft, Tesla & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Tesla (TSLA) and Thermo Fisher Scientific (TMO).
Company News for Jul 23, 2020
by Zacks Equity Research
Companies In The News Are: HCA, TMO, ABB, APH.
Should You Buy the Rally in Non-US Stocks?
by John Blank
Or does global growth need to show up first???
Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Thermo Fisher (TMO) Q2 Earnings Beat on COVID-19-Led Sales
by Zacks Equity Research
We are encouraged about Thermo Fisher's (TMO) exceptionally strong year-over-year revenue growth at Life Sciences Solutions segment.
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Can Diagnostics Aid Hologic (HOLX) Q3 Earnings Amid Coronavirus?
by Zacks Equity Research
Strength in segmental business is likely to have aided Hologic's (HOLX) performance in third-quarter fiscal 2020 amid the coronavirus-led economic doldrums.
Thermo Fisher Scientific (TMO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 45.69% and 0.10%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Growing Testing Capacity to Aid LabCorp's (LH) Q2 Earnings?
by Zacks Equity Research
LabCorp's (LH) developments to support COVID-19 testing are believed to have contributed to the company's second-quarter earnings.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Lithia Motors, Quest Diagnostics, Pool and Boston Beer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Lithia Motors, Quest Diagnostics, Pool and Boston Beer
Why Earnings Season Could Be Great for Thermo Fisher (TMO)
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Top Stocks to Buy Ahead of Earnings Release
by Zacks Equity Research
Healthcare, consumer staples and retail sectors could be ideal investments right now, keeping in mind the growing demand for their products.
Amkor (AMKR) Gears Up for Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Healthy growth in the consumer and communication end market is likely to reflect on Amkor Technology's (AMKR) Q2 results. Yet, uncertainty owing to the coronavirus outbreak may have been a concern.